Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1345 + Afluria Quadrivalent
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1345 + Afluria Quadrivalent is a coadministration regimen consisting of Moderna's investigational mRNA-based respiratory syncytial virus (RSV) vaccine, mRNA-1345, and Seqirus's licensed quadrivalent inactivated influenza vaccine, Afluria Quadrivalent. mRNA-1345 encodes for the stabilized prefusion F glycoprotein of RSV-A to elicit neutralizing antibodies. Afluria Quadrivalent is a split-virion inactivated vaccine containing antigens from two influenza A subtypes and two influenza B lineages. This regimen is being evaluated in clinical trials to support the simultaneous administration of both vaccines during a single healthcare visit, particularly in older adults, to improve vaccination compliance and provide protection against both seasonal influenza and RSV.
- Brand names
- mRESVIAAfluria Quadrivalent
- Other names
- mRNA-1345 + QIVRSV vaccine + influenza vaccine coadministration
02
Targets
RSV F (Respiratory syncytial virus fusion protein)HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on mRNA-1345 + Afluria Quadrivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1345 + Afluria Quadrivalent.